89 results about "Glandular hyperplasia" patented technology

The invention provides application of Fe3O4 nanoparticles in preparation of a medicine for treating benign prostatic hyperplasia, and relates to the technical field of biological medicines. The invention further discloses application of the Fe3O4 nano-particles in preparation of a medicine for treating benign prostatic hyperplasia. The research result of the invention emphasizes that the ferroferric oxide nanoparticles are a promising candidate drug for targeted therapy of BPH and related prostate diseases, and new possibility is provided for treatment intervention of urinary surgery. The inventor studies the effect of the Fe3O4 nanoparticles in inhibiting benign prostatic hyperplasia. Results of the inventor show that the nanoparticles not only effectively reduce the proliferation rate of prostate cells, but also improve related biochemical indexes. Therefore, the polypeptide has potential application in treatment of prostatic hyperplasia.

The invention belongs to the field of biological pharmacy, and provides keratin YK93-5, a coding nucleic acid molecule thereof, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method and a pharmaceutical composition of the keratin YK93-5. The invention also provides application of the keratin YK93-5 and other products in preparation of drugs for treating lung cancer, lymphoma, breast cancer, melanoma, hysteromyoma, prostatic hyperplasia and the like.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a pharmaceutical composition for treating benign prostatic hyperplasia and a preparation method thereof. The composition is prepared from the following medicinal materials in parts by weight: 6 to 8 parts of radix aconiti lateralis preparata, 3 to 5 parts of cortex cinnamomi, 10 to 15 parts of fructus alpiniae oxyphyllae, 10 to 15 parts of fructus psoraleae, 5 to 10 parts of semen myristicae, 5 to 10 parts of ground beeltle, 8 to 12 parts of spina gleditsiae, 10 to 15 parts of radix angelicae sinensis, 8 to 12 parts of radix linderae, 15 to 20 parts of radix rehmanniae praeparata, 10 to 15 parts of fructus corni, 8 to 12 parts of rhizoma anemarrhenae, 15 to 20 parts of radix scrophulariae, 8 to 12 parts of rhizoma alismatis, 5 to 10 parts of radix stephaniae tetrandrae and 10 to 15 parts of radix cyathulae. The invention provides the self-prepared medicine composition for treating the prostatic hyperplasia, the diseases of patients with the prostatic hyperplasia are remarkably improved through the synergistic effect of all the medicines in the composition, and a new traditional Chinese medicine treatment thought is provided for clinical treatment of the BPH disease. According to the traditional Chinese medicine composition, medicine pairs are increased or decreased on the basis of referring to a traditional Chinese medicine classic treatment compound, the unique traditional Chinese medicine composition is finally formed, and all the medicine pairs in the formula cooperate with one another and are indispensable.

This invention relates to the application of ALKBH5 as a target in the preparation of drugs for inhibiting the progression of TNBC, and to the drugs themselves. This application discovers mRNA m 6 The alpha-modifying demethylase ALKBH5 is specifically highly expressed in triple-negative breast cancer (TNC). Using spontaneous TNC models and xenograft tumor models, knockout or knockdown of ALKBH5 significantly inhibited breast hyperplasia and the development of TNC, and promoted tumor differentiation. Simultaneously, the specific inhibitor EN300-14040 of ALKBH5 significantly inhibited the growth of TNC organoids, promoted TNC cell differentiation, and enhanced the sensitivity of TNC organoids to the endocrine drug 4OH-T, exhibiting a synergistic inhibitory effect with 4OH-T. Therefore, ALKBH5 represents a potential novel therapeutic target for TNC, and ALKBH5 inhibitors are a potential new type of drug for the treatment of TNC.

The invention belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for treating or improving prostate diseases and stomach diseases, a traditional Chinese medicine preparation and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw materials: Chinese lobelia, tripterygium wilfordii, selfheal, dandelion, lophatherum gracile, hydrocotyle verticillata and liquorice. The traditional Chinese medicine composition disclosed by the invention is reasonable in compatibility and synergistic in efficacy, can treat prostate diseases such as chronic prostatitis and benign prostatic hyperplasia and stomach diseases such as chronic gastritis and gastric ulcer at the same time by taking a treatment method of clearing away heat and toxic materials, promoting diuresis and treating stranguria, regulating qi and harmonizing stomach and removing stasis and diminishing swelling, has the advantages of definite curative effect, high safety, low recurrence rate, convenience in taking and the like, and is suitable for clinical popularization.

The application discloses application of a reagent for detecting LRRN3 expression level in preparation of a benign prostatic hyperplasia diagnosis product. It is proved through cell function experiments and animal experiments that overexpression of the LRRN3 gene can inhibit the proliferation of prostate cells, block the cell cycle and promote cell apoptosis, thereby effectively inhibiting the prostatic hyperplasia. The discovery provides a new target and treatment strategy for the treatment of the prostatic hyperplasia, and provides a brand-new thought and method for the treatment of the prostatic hyperplasia. Based on the research results, a gene therapy drug taking the LRRN3 gene as a target can be further developed, for example, a lentivirus vector carrying the LRRN3 gene or other gene delivery systems are constructed and used for the treatment of the prostatic hyperplasia. In addition, the LRRN3 gene can be combined with other treatment methods to improve the treatment effect.

The invention discloses 5 alpha-reductase degradation molecules as well as a preparation method and application thereof, four 5 alpha-reductase degradation molecules can realize thorough removal of zymoprotein by inducing proteasome-dependent degradation of 5 alpha-reductase instead of only inhibiting the activity of the 5 alpha-reductase, so that a more lasting treatment effect is obtained; under the condition of equal dosage, the effect of the 5 alpha-reductase degradation molecule on treating the benign prostatic hyperplasia is superior to that of the traditional inhibitor finasteride; the four kinds of 5 alpha-reductase degrading molecules can effectively degrade 5 alpha-reductase protein and remarkably inhibit development of benign prostatic hyperplasia, have good biological safety and provide new strategies and candidate drugs for treatment of diseases related to 5 alpha-reductase such as benign prostatic hyperplasia, prostatic cancer, androgenetic alopecia and acne.

The invention discloses a traditional Chinese medicine formula for treating hyperplasia of mammary glands and breast cancer and a preparation method thereof. The formula comprises radix paeoniae rubra, pseudo-ginseng, radix aucklandiae, swim bladder, angelica sinensis, blister beetle, rhizoma atractylodis macrocephalae and scorpion which are compatible according to a specific proportion. The preparation method comprises the following steps: adding water to soak the five medicinal materials such as red paeony root (1 hour in summer and 2 hours in winter), adding the swim bladder, decocting until the liquid medicine is sticky, grinding the baked cantharides and scorpion into powder, and mixing. Based on theories such as the holism concept of traditional Chinese medicine, multiple modules take effect synergistically, microcirculation can be improved, immunity can be enhanced, cancer cell apoptosis can be induced, the total effective rate for hyperplasia of mammary glands is 96.7%, and the total effective rate for I-II stage breast cancer reaches 86.7%. The traditional Chinese medicine is flexible to take, high in safety and suitable for long-term treatment.

The invention discloses a mammary gland hyperplasia therapeutic instrument, and belongs to the field of mammary gland therapeutic instruments. A mammary gland hyperplasia therapeutic apparatus comprises a machine body and an ultrasonic treatment head, the ultrasonic treatment head is electrically connected with the machine body, a support is placed on the machine body, and paired mammary gland covers are arranged on the support; a connecting head is arranged at the top end of the breast cover, a servo motor is connected in the connecting head, a first arc-shaped rod is connected to the driving end of the servo motor, an adjusting sliding hole is formed in the first arc-shaped rod, an adjusting sliding block is slidably connected in the adjusting sliding hole, a connecting rod is connected to the adjusting sliding block, and the connecting rod is connected to the adjusting sliding block. The ultrasonic treatment head is connected to the connecting rod; the servo motor drives the first arc-shaped rod to rotate, the ultrasonic treatment head is attached to the mammary gland, circumferential massage is conducted along the periphery of the mammary gland along with the first arc-shaped rod, and the ultrasonic treatment head does not need to be manually held for a long time.

The invention discloses a preparation method of a fallen fruit extract and application of the fallen fruit extract in prevention or treatment of hyperplasia of mammary glands. The extract is prepared by extracting immature fruits (fallen fruits) of a traditional Chinese medicinal material Citrus chachiensis through a water decoction method. Experiments prove that the dropped fruit extract can significantly reduce the height and diameter of mammary gland tissues of a mammary gland hyperplasia model rat, significantly reduce the thickness of mammary glands, effectively improve abnormal deposition of collagenous fibers around acelles, and reverse typical proliferative pathological changes of the mammary gland tissues. The invention provides a safe and effective new candidate medicine or functional food raw material for prevention and treatment of hyperplasia of mammary glands, realizes high-valued utilization of citrus chachiensis fallen fruit resources, and has a good application prospect.

A method of treating Sebaceous Hyperplasia (SH) using a 1726 nm laser pulse that selectively targets sebum produced by the sebaceous glands.

The invention relates to application of pulsatilla saponin D in preparation of a medicine for preventing or treating human prostatic hyperplasia. The invention shows that the pulsatilla saponin D has an inhibition effect on human prostate cell WPMY-1, HPRF and BPH-1 cell strains, and can cause cell apoptosis to a certain extent, so that the pulsatilla saponin D shows the effect of preventing or treating prostatic hyperplasia.

This invention relates to a novel use of propargylcysteine ​​in the preparation of anti-mastopathy drugs. The invention discovers that S-propargylcysteine ​​can improve E2 / P imbalance by regulating HPO axis function and inhibiting abnormal activation of the GnRH-sex hormone axis; it also reduces the inflammatory microenvironment by inhibiting the release of inflammatory factors; ultimately, it downregulates ER / PR-mediated proliferation signals and inhibits PCNA expression locally in the breast. Through multi-target regulation of neuroendocrine, inflammatory responses, and proliferation-related signaling pathways, it effectively alleviates breast hyperplasia and its associated chronic stress-induced depressive-like behaviors, thus exerting anti-mastopathy and therapeutic effects on breast hyperplasia complicated with depression.

The invention provides a traditional Chinese medicine composition for treating hyperplasia of mammary glands as well as a preparation and application thereof, and relates to the field of medicines. The traditional Chinese medicine composition for treating hyperplasia of mammary glands is prepared from the following raw material medicines in parts by weight: 13 to 18 parts of radix linderae, 4 to 6 parts of fructus amomi, 8 to 12 parts of rhizoma cyperi, 8 to 12 parts of radix aucklandiae, 8 to 12 parts of liquorice root, 13 to 18 parts of rhizoma corydalis, 13 to 18 parts of radix scrophulariae, 18 to 23 parts of oyster, 4 to 6 parts of spica prunellae, 8 to 12 parts of bulbus fritillariae thunbergii, 18 to 23 parts of herba taraxaci, 13 to 18 parts of loofah sponge, 13 to 18 parts of rhizoma zingiberis recens, 18 to 23 parts of semen citri reticulatae and 13 to 18 parts of paederia scandens. The traditional Chinese medicine composition can be prepared into decoction or granules. In the traditional Chinese medicine composition, the combined spicebush root and the nutgrass galingale rhizome are combined as monarch drugs; corydalis tuber is used as a ministerial drug; costustoot, fructus amomi, loofah sponge, tangerine seed, radix scrophulariae, oyster, selfheal, dandelion and thunberg fritillary bulb are combined as adjuvant drugs; the ginger and the liquorice are used as assistants and guides; the medicines are matched and supplement each other to jointly achieve the effects of promoting qi circulation and soothing liver, promoting blood circulation to remove blood stasis and eliminating stagnation and relieving pain, so that qi circulation and blood circulation are smooth, depression is dispersed and pain is relieved, and the traditional Chinese medicine has a good curative effect on treating hyperplasia of mammary glands.

The application discloses application of a reagent for detecting AHSP protein in preparation of a product for diagnosing prostate cancer, and relates to the technical field of biological medicine; through proteomic analysis, ELISA test on urine protein of prostate cancer patients, clear cell renal cell carcinoma patients and normal healthy men, and immunohistochemical analysis on file wax blocks of the prostate cancer patients, normal prostate tissues around the cancer, prostate tissues of prostatic hyperplasia and clear cell renal cell carcinoma tissues, it is found that the AHSP protein has a certain relationship with the occurrence and development of prostate cancer, and can be used for assisting diagnosis of the prostate cancer; and in urine detection, AHSP has higher sensitivity than PSA, and when PSA is negative or serum PSA is low, AHSP can form complementation with ASHP, thereby helping to improve the diagnosis rate and non-invasive screening ability; through research on the relationship between the AHSP protein and the prostate cancer, the diagnosis rate of patients can be improved, non-invasive reexamination after treatment is facilitated, drug use is guided, and the survival rate is improved.

The application discloses an application of a prostate hyperplasia related marker in preparation of a product for detecting prostate hyperplasia, and the prostate hyperplasia related marker is at least one selected from MINP1, ACTBL and APOC4 proteins. In the technical scheme, MINP1, ACTBL and APOC4 are combined as a detection marker for prostate hyperplasia (BPH), so that the complementarity of the three in different stages of diseases can be fully exerted, and the comprehensive performance of the detection product is obviously improved. MINP1 and ACTBL participate in disease progression by regulating prostate cell proliferation and apoptosis, and APOC4 can present significant expression changes in blood cells of early BPH patients, so that BPH disease screening can be accurately performed. When the three are applied in cooperation, early screening of BPH can be realized, and the activity and severity of the lesion can be evaluated, so that a detection system covering the whole process of disease occurrence and development is formed, the limitation of a single marker in the diagnosis dimension is effectively made up, and the comprehensiveness and accuracy of BPH detection are greatly improved.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition for treating benign prostatic hyperplasia and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 5 to 10 parts of leech, 5 to 10 parts of centipede, 2 to 5 parts of earthworm, 2 to 5 parts of cicada slough, 2 to 5 parts of silkworm chrysalis, 2 to 5 parts of radix achyranthis bidentatae, 2 to 5 parts of pericarpium citri reticulatae, 2 to 5 parts of gecko and 5 to 10 parts of poria cocos. According to the traditional Chinese medicine composition, the formula is reasonably combined through monarch, minister, assistant and guide in traditional Chinese medicine, the medicine effect is maximized through the modern technology, and the effect of treating prostatic hyperplasia is achieved.

The invention discloses nucleus eliminating granules which are prepared by the following steps: adding water into 12 medicinal materials, namely selfheal, oyster, kelp, beautiful sweetgum fruit, fructus aurantii, cowherb seed, salvia miltiorrhiza, curcuma zedoary, ligusticum wallichii, white paeony root, corydalis tuber and radix bupleuri, heating, extracting, filtering, concentrating and drying to obtain medicinal powder; and sieving, adding auxiliary materials, adding a wetting agent, preparing a soft material, granulating, and drying to obtain the kernel eliminating granules. The invention further discloses a preparation method of the nucleus eliminating particles, a thin-layer chromatography identification and content determination method and application of the nucleus eliminating particles. According to the invention, the nucleus-eliminating mixture is developed into the nucleus-eliminating particles, the forming rate, the dissolution rate, the moisture absorption rate, the fluidity and the like of the nucleus-eliminating particles all meet the requirements of Chinese Pharmacopoeia, and the stability experiment result shows that the product stability is good; the curative effect of the nucleus eliminating granules on breast pain, breast nodules, hyperplasia of mammary glands and breast diseases can be achieved; doctors realize accurate medication under treatment based on syndrome differentiation, and the flexibility of adjusting prescriptions along with symptoms is guaranteed; on the other hand, more convenient carrying and taking experience can be provided for the patient.

The invention discloses a minimally invasive surgery treatment system for benign prostatic hyperplasia and a use method of the minimally invasive surgery treatment system. The system comprises an outer cannula used for entering the body of a patient through the urethra, a handle connected to the outer cannula, a cannula installed in the outer cannula, a stretching tube installed in the cannula, a guide wire installed in the stretching tube, a puncture needle head installed at the free end of the guide wire, a rotation driving mechanism used for driving the guide wire to rotate and a telescopic driving mechanism used for driving the cannula to move. A plurality of cutting knives which are uniformly arranged around the stretching tube are arranged between the free end of the stretching tube and the puncture needle head; a magnetic ring which is magnetically attracted with the puncture needle head is arranged at the free end of the sleeve; a guide wire locking mechanism used for locking the guide wire and a stretching pipe adjusting and locking mechanism used for adjusting the position of the stretching pipe and locking the stretching pipe are further arranged in the handle. The system is reasonable in structural design, the telescopic cutting knife is integrated into the puncture assembly, when the system is used for operation, trauma is small, recovery is fast, only local anesthesia is needed, the effect is fast, and the operation effect is good.

The application provides application of a CFTR corrector in preparation of a drug for treating mammary gland hyperplasia, and belongs to the field of biopharmacy.The application creatively finds, through non-clinical pharmacodynamics test, that a compound represented by formula I, tizacatol, can significantly reduce the nipple diameter, height and uterus index of a mammary gland hyperplasia rat model, relieve mammary gland hyperplasia, and improve the content level of E2 and PROG in serum, and has a good treatment effect in treating mammary gland hyperplasia, and has the potential of being applied in preparation of a drug for treating mammary gland hyperplasia.

The invention relates to the technical field of medicinal liquor, in particular to medicinal liquor special for treating prostate diseases. 420g to 500g of Chinese yam; 420 g to 500 g of prepared rehmannia root; 420g to 500g of semen euryales; the weight of the cornus officinalis is 450 to 500 grams; 150 g to 180 g of syngnathus; 390-450 g of lotus seeds; and 5000-5500 g of sorghum liquor with the alcohol content of 62%. The medicinal liquor contains effective components of Chinese yam, gordon euryale seed, dogwood, lotus seed, syngnathus and stir-fried Chinese chive seed, 62-degree kaoliang spirit is selected as a solvent, the alcoholic strength is moderate, the effective components in the medicinal materials are fully extracted, the medicinal liquor has a remarkable treatment effect, and related symptoms of prostate diseases can be effectively relieved; after the medicinal liquor is prepared, a patient only needs to take the medicinal liquor according to the specified taking time and dosage, complicated operation or additional treatment equipment is not needed, and the medicinal liquor is suitable for patients with various types of prostate diseases, including prostatitis, prostatic hyperplasia and the like, has a wide application prospect, and has a cure effect of 100%.

The present invention relates to a pharmaceutical composition, a food composition and a feed composition for preventing, ameliorating or treating benign prostatic hyperplasia, each composition comprising an Alpiniae oxyphyllae Fructus extract, and a method for treating benign prostatic hyperplasia by using the pharmaceutical composition. The pharmaceutical composition, the food composition, and the feed composition exhibit the effect of inhibiting prostatic hypertrophy caused by male hormone imbalance, can reduce lower urinary tract symptoms caused by prostatic hypertrophy by inhibiting prostatic proliferation, and can be developed, through non-clinical and clinical studies, as pharmaceuticals that are effective in preventing and treating benign prostatic hyperplasia, health functional foods and health foods that are beneficial to prostate health, and the like.

The present disclosure relates to an instrument for treating benign prostatic hyperplasia. The instrument comprises a catheter, a microneedle and a handle brake, a plurality of micropores are formed in the guide pipe in the first direction and the second direction at intervals; the microneedle is slidably arranged in the catheter, and the far end of the microneedle can extend out of the catheter through the micropore; the handle brake comprises a supporting part, a positioning part, a limiting part and a pushing part which are sequentially connected, the pricking position of the microneedle can be adjusted in a multi-degree-of-freedom mode by adjusting the handle brake, the problem that damage is caused due to the fact that an instrument is prone to being rubbed and pulled with a cavity is solved, and meanwhile the device has the advantages of being easy to operate and efficient.

The invention provides novel laser treatment equipment for prostatic hyperplasia in urinary surgery, and relates to the technical field of laser treatment. The novel laser treatment equipment for urinary surgery prostatic hyperplasia comprises a main body, a placement groove is formed in the center of the upper end face of the main body, a display device is arranged at the position, close to the edge of one side, of the inner center of the placement groove, and the two ends of the display device are rotationally connected to the two inner side walls of the placement groove respectively; a control panel is arranged at the position, close to the other side, of the center of the lower inner wall of the containing groove, a treatment system is arranged in the main body, and the treatment system comprises a laser emitting device, an energy control module, an optical fiber catheter, an image guiding system, a cooling system and a control system. Through an intelligent energy control algorithm and a multi-stage safety protection mechanism, precise control over laser energy is ensured, damage to surrounding healthy tissue is reduced, precise control over energy in the treatment process is ensured, and tissue damage caused by too high or too low energy is prevented.

The invention discloses application of a prostatic hyperplasia related marker in preparation of a product for detecting prostatic hyperplasia. The prostatic hyperplasia related marker is selected from at least one of MINP1, ACTBL and APOC4 protein. In the technical scheme provided by the invention, MINP1, ACTBL and APOC4 are combined as the BPH detection marker, complementarity of the MINP1, ACTBL and APOC4 in different stages of diseases can be fully exerted, and the comprehensive efficiency of a detection product is remarkably improved. Wherein MINP1 and ACTBL participate in disease progression by regulating prostate cell proliferation and apoptosis, APOC4 can present significant expression change in blood cells of an early-stage BPH patient, and BPH disease screening can be accurately carried out. When the three markers are synergistically applied, early screening of BPH can be realized, lesion activity and severity can be evaluated, a detection system covering the whole course of disease occurrence and development is formed, the limitation of a single marker on the diagnosis dimension is effectively made up, and the comprehensiveness and accuracy of BPH detection are greatly improved.

This invention discloses a rehabilitation training device for benign prostatic hyperplasia (BPH), comprising: a seat plate, two buttock cushions, a compression spring, two assessment mechanisms, and a transmission mechanism. A support frame is provided below the seat plate, and a support rod is provided on the top surface. Leg perforations are provided on the seat plate. The two buttock cushions are slidably fitted onto the support rod. The compression spring is connected between the two sliders. The two assessment mechanisms are located on the top surface of the seat plate, and each assessment mechanism includes: a drive gear, a driven gear, a pointer, a dial, and a lever. The drive gear and the driven gear mesh with each other. The dial is fitted onto the gear shaft of the driven gear. One end of the pointer is connected to the center point of the driven gear, and the other end points to the scale of the dial. One end of the lever is connected to the center of the drive gear, and the other end faces the buttock cushions. The transmission mechanism is located on the seat plate and is used to transmit the slider feed amount to the assessment mechanisms. This invention can assist patients in performing Kegel exercises and can assess the effectiveness of the patients' Kegel exercises.

The invention discloses a traditional Chinese medicine composition for treating hyperplasia of mammary glands and precancerous lesions, a traditional Chinese medicine preparation and a preparation method of the traditional Chinese medicine composition. Comprising 8-12 parts of vinegar-processed radix bupleuri, 12-18 parts of radix paeoniae alba, 12-18 parts of selfheal, 9.5-14.5 parts of thunberg fritillary bulb, 8-12 parts of vinegar-processed curcuma zedoary, 8-12 parts of radix curcumae, 12-18 parts of bighead atractylodes rhizome, 12-18 parts of poria cocos, 12-18 parts of raw oyster shell, 12-18 parts of hedyotis diffusa, 6.4-9.6 parts of schisandra chinensis, 9.5-14.5 parts of glossy privet fruit, 8-12 parts of vinegar-processed turtle shell, 8-12 parts of astragalus membranaceus and 4.8-7.2 parts of honey-fried licorice root. The traditional Chinese medicine composition has the effects of soothing the liver, strengthening the spleen, reducing phlegm, resolving masses, activating blood and eliminating diseases, and can be used for treating hormone-dependent proliferative diseases such as hyperplasia of mammary glands and atypical hyperplasia Multi-target intervention is achieved, the curative effect is remarkable, side effects are small, and wide market and application prospects are achieved.

The invention provides a 5 alpha-reductase inhibitor. The inhibitor is pawpaw total triterpenes (TCS). The invention also provides application of the pawpaw total triterpenes TCS in preparation of drugs for treating benign prostatic hyperplasia. TCS and UA have no obvious toxic and side effects on visceral organs of each group of rats; the thickness of glandular epithelial cells in a TCS group is remarkably reduced, the 5AR activity of the TCS group is remarkably reduced, the T level is remarkably reduced, and the DTH level is remarkably reduced; the blood sugar of the TCS group is obviously reduced, the concentration of total cholesterol and low-density lipoprotein is obviously reduced, and the TCS can obviously increase the high-density lipoprotein level and reduce the content of triglyceride. The results show that the TCS and the main component tartaric acid have a remarkable inhibiting effect on prostatic hyperplasia. The inhibition of 5AR activity and the reduction of DHT generation and T content are one of the action mechanisms, and the important characteristic is that the prostatic hyperplasia can be inhibited and abnormal blood sugar and blood fat can be regulated at the same time.

The invention provides an essential oil composition for improving dysmenorrhea and hyperplasia of mammary glands caused by liver depression and qi stagnation. The essential oil composition is prepared from the following raw materials in parts by weight: 0.5-1.5 parts of angelica sinensis essential oil and 0.5-1.5 parts of rhizoma cyperi essential oil. The invention also provides application of the essential oil composition in preparation of external medicines for improving hyperplasia of mammary glands caused by liver depression and qi stagnation. The traditional Chinese medicine composition overcomes the defects of single treatment effect, poor patient compliance, more side effects, inconvenience in use and the like in the prior art, can prevent and treat various diseases such as dysmenorrhea, hyperplasia of mammary glands and the like caused by liver depression and qi stagnation, and is scientific and simple in prescription compatibility, convenient to use, high in safety, fragrant in smell and high in patient compliance.

The invention discloses a method for analyzing an action mechanism of a breast nodule removing tablet. The method comprises the following steps: identifying chemical components of the breast nodule removing tablets; predicting effective target spots of the chemical components based on network pharmacology, and predicting target spots of hyperplasia of mammary glands; and performing clustering analysis and other operations on the relative content of differential proteins in the mammary gland hyperplasia model before and after the breast nodule removing tablets are taken based on proteomics. According to the application, a method for integrating multi-dimensional data through a'chemical component-target network-omics technology 'is used for discussing the action mechanism of the breast nodule removing tablets, important proteins, metabolites or pathways are screened out, research targets are more easily locked, and the action mechanism of the traditional Chinese medicine compound breast nodule removing tablets is disclosed.